Acumen Pharmaceuticals, Inc. (ABOS) has a negative trailing P/E of -1.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -76.91%.
Criteria proven by this page:
Overall SharesGrow Score: 50/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2019 | -72.8 | 0.00 | -50.43 | 339.36 | - |
| 2020 | -78.6 | -2.62 | -30.98 | 401.05 | - |
| 2021 | -2.6 | 0.00 | 1.15 | 0.00 | - |
| 2022 | -5.1 | 0.09 | 1.16 | 0.00 | - |
| 2023 | -3.6 | -1.88 | 0.70 | 0.00 | - |
| 2024 | -1.0 | -0.02 | 0.57 | 0.00 | - |
| 2025 | -1.1 | -0.06 | 1.81 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2019 | $-0.20 | $1.7M | $-7.86M | -463.3% |
| 2020 | $-0.26 | $1.44M | $-7.33M | -510.1% |
| 2021 | $-5.02 | $0.00 | $-100.61M | - |
| 2022 | $-1.06 | $0.00 | $-42.86M | - |
| 2023 | $-1.08 | $0.00 | $-52.37M | - |
| 2024 | $-1.71 | $0.00 | $-102.33M | - |
| 2025 | $-2.00 | $0.00 | $-121.34M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.65 | $-2.17 – $-1.04 | $0.00 | $0.00 – $0.00 | 3 |
| 2027 | $-1.56 | $-1.56 – $-1.56 | $0.00 | $0.00 – $0.00 | 1 |
| 2028 | $-1.21 | $-1.81 – $-0.61 | $26.53M | $26.53M – $26.53M | 2 |
| 2029 | $-1.22 | $-1.22 – $-1.22 | $56.19M | $56.19M – $56.19M | 1 |
